HRS-4642

Phase 2Small molecule

HRS-4642 is one of 170 small molecule programs targeting Locally Advanced Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

169

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Pancreatic CancerRecruiting

Pancreatic CancerRecruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Patients With Advanced Solid TumorsActive, not recruiting

Advanced Solid TumorsRecruiting

Locally Advanced Pancreatic CancerPhase 2

Recruiting

Pancreatic CancerPhase 2

Recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

HRS-4642

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

4 2

Byetta

AstraZeneca

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06773130

Q3 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06520488

Q4 2027

Phase 2Recruiting

Locally Advanced Pancreatic Cancer

NCT07438106

Q1 2028

Phase 2Recruiting

Pancreatic Cancer

NCT06770452

Clinical

Trials by Indication[1]

Pancreatic Cancer4 trials

Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer

Recruiting·FFudan University·Phase 1/2·NCT06427239·35 enrolled

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Recruiting·ZZhejiang University·Phase 2·NCT06770452·32 enrolled

An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06938282·60 enrolled

Show 1 more trial

An Exploratory Clinical Study of HRS-4642 in Combination With Chemotherapy With or Without Adebrelimab as Neoadjuvant Therapy for Pancreatic Cancer

Not yet recruiting·CChanghai Hospital·Phase 2·NCT07691593·60 enrolled

Patients With Advanced Solid Tumors2 trials

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05533463·102 enrolled

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT06385678·47 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·WWest China Hospital·Phase 1/2·NCT06773130·20 enrolled

Advanced Solid Tumors1 trial

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT06520488·118 enrolled

Locally Advanced Pancreatic Cancer1 trial

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07438106·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for HRS-4642. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-4642 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-4642. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

HRS-4642

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Pancreatic Cancer4 trials

Patients With Advanced Solid Tumors2 trials

Pancreatic Ductal Adenocarcinoma1 trial

Advanced Solid Tumors1 trial

Locally Advanced Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News